475 related articles for article (PubMed ID: 25739674)
1. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.
Song S; Honjo S; Jin J; Chang SS; Scott AW; Chen Q; Kalhor N; Correa AM; Hofstetter WL; Albarracin CT; Wu TT; Johnson RL; Hung MC; Ajani JA
Clin Cancer Res; 2015 Jun; 21(11):2580-90. PubMed ID: 25739674
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
3. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
4. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties.
Song S; Ajani JA; Honjo S; Maru DM; Chen Q; Scott AW; Heallen TR; Xiao L; Hofstetter WL; Weston B; Lee JH; Wadhwa R; Sudo K; Stroehlein JR; Martin JF; Hung MC; Johnson RL
Cancer Res; 2014 Aug; 74(15):4170-82. PubMed ID: 24906622
[TBL] [Abstract][Full Text] [Related]
5. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
[TBL] [Abstract][Full Text] [Related]
6. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
7. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
[TBL] [Abstract][Full Text] [Related]
8. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
Yan R; Liang ZW; Liu HS; Ge Y; An GY
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
[No Abstract] [Full Text] [Related]
9. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
[TBL] [Abstract][Full Text] [Related]
10. FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells.
Pei Y; Sun X; Guo X; Yin H; Wang L; Tian F; Jing H; Liang X; Xu J; Shi P
Oncol Rep; 2017 Oct; 38(4):2205-2210. PubMed ID: 28791365
[TBL] [Abstract][Full Text] [Related]
11. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.
Xu Y; Li Y; Jin J; Han G; Sun C; Pizzi MP; Huo L; Scott A; Wang Y; Ma L; Lee JH; Bhutani MS; Weston B; Vellano C; Yang L; Lin C; Kim Y; MacLeod AR; Wang L; Wang Z; Song S; Ajani JA
Mol Cancer; 2019 Oct; 18(1):141. PubMed ID: 31601234
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
13. A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma.
Song S; Xie M; Scott AW; Jin J; Ma L; Dong X; Skinner HD; Johnson RL; Ding S; Ajani JA
Mol Cancer Ther; 2018 Feb; 17(2):443-454. PubMed ID: 29167315
[TBL] [Abstract][Full Text] [Related]
14. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
15. Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth.
Maruyama J; Inami K; Michishita F; Jiang X; Iwasa H; Nakagawa K; Ishigami-Yuasa M; Kagechika H; Miyamura N; Hirayama J; Nishina H; Nogawa D; Yamamoto K; Hata Y
Mol Cancer Res; 2018 Feb; 16(2):197-211. PubMed ID: 29061667
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Islam SS; Uddin M; Noman ASM; Akter H; Dity NJ; Basiruzzman M; Uddin F; Ahsan J; Annoor S; Alaiya AA; Al-Alwan M; Yeger H; Farhat WA
EBioMedicine; 2019 May; 43():211-224. PubMed ID: 31085100
[TBL] [Abstract][Full Text] [Related]
18. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
19. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
20. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance.
Li Y; Wang S; Wei X; Zhang S; Song Z; Chen X; Zhang J
Cancer Sci; 2019 Feb; 110(2):561-567. PubMed ID: 30467925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
